Clinical Operations
Clinical Project ManagementStudy Monitoring and Site ManagementTrial Master File and Document ManagementQuality and Vendor Management SystemsStudy DocumentsRegulatory Affairs
Regulatory StrategyRegulatory WritingAgency Communications and SubmissionsDocument Editorial, QC and SubmissionQC, Review and RedactionLegal RepresentationPharmacovigilanceILAP SubmissionsMedical Communications
Publication PlanningStrategic CommunicationsScientific CommunicationsMedical EducationMedical IllustrationGrant Applications and Project PartnershipNanomerics’ mission is to deliver augmented medicines with improved activity and fewer associated side effects through the application of materials science. Services provided by Niche included:
Nanomerics’ mission is to deliver augmented medicines with improved activity and fewer associated side effects.
The company has generated an extensive intellectual property portfolio in addition to in-licensing key assets. Founded by Professors Uchegbu and Schätzlein in 2010, Nanomerics exploits the findings made in their respective laboratories at Strathclyde University and University College London. Their molecularly engineered materials are designed to enhance targeted delivery of existing and novel drug molecules.
Niche began discussing Nanomerics’ clinical ambitions in 2016, with the company’s clinical strategy coming into focus in early 2021. Niche was invited to provide support for the development of the regulatory documentation for OC134, a reformulation of tacrolimus targeting severe atopic keratoconjunctivitis and vernal keratoconjunctivitis. The Niche team’s expertise in the preparation of IBs and its previous experience with tacrolimus meant that it quickly and efficiently developed the necessary regulatory submission documentation. The Investigator’s Brochure and Investigational Medicinal Product Dossier were based on information from the scientific literature and incorporated Nanomerics’ pre-clinical experimental data.
Niche became a crucial component in the clinical trial planning team, taking part in regular mapping and strategy meetings as the submission deadline approached. Niche team members worked closely with both Nanomerics and the study physician, based at Moorfields Hospital, to develop a robust clinical study protocol to examine the safety and tolerability of OC134 in human volunteers. This is called Sunlight Trial and is the first of Nanomerics’ planned clinical projects.
Niche also supported the Nanomerics team in the development of the ILAP submission, conduct of the ILAP meeting and development of the TDP for OC134.